A medical-legal review of power morcellation in the face of the recent FDA warning and litigation

Raquel Ton, Gokhan Kilic, John Phelps

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Minimally invasive gynecologic surgeons who perform laparoscopic intraperitoneal morcellation should be aware of the recent US Food and Drug Administration (FDA) warning and litigation arising from use of morcellation devices with claims of intraperitoneal dissemination of cancerous cells. On November 24, 2014, the FDA issued a statement warning against using laparoscopic power morcellators in the majority of women undergoing hysterectomy or myomectomy for uterine fibroids. Despite the best intentions in regards to their patients, gynecologists who continue to use power morcellation devices expose themselves to liability. This article is not meant to further deter gynecologists from using laparoscopic power morcellators, but rather to provide an interpretation of the FDA statement as to the patients for whom the use of power morcellation may still be permitted under the FDA guidelines. This article also offers protective measures from a legal perspective for those who choose to continue to use power morcellation in the face of the recent FDA warning and litigation.

Original languageEnglish (US)
Pages (from-to)564-572
Number of pages9
JournalJournal of Minimally Invasive Gynecology
Volume22
Issue number4
DOIs
StatePublished - May 1 2015

Fingerprint

Jurisprudence
United States Food and Drug Administration
Uterine Myomectomy
Equipment and Supplies
Leiomyoma
Hysterectomy
Morcellation
Power (Psychology)
Guidelines

Keywords

  • Boxed warning
  • Consent
  • FDA
  • Fibroids
  • Leiomyosarcoma
  • Liability
  • Litigation
  • Morcellation
  • Morcellator

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

A medical-legal review of power morcellation in the face of the recent FDA warning and litigation. / Ton, Raquel; Kilic, Gokhan; Phelps, John.

In: Journal of Minimally Invasive Gynecology, Vol. 22, No. 4, 01.05.2015, p. 564-572.

Research output: Contribution to journalArticle

@article{2fbcc822f9e54a66bdc678a982649cfc,
title = "A medical-legal review of power morcellation in the face of the recent FDA warning and litigation",
abstract = "Minimally invasive gynecologic surgeons who perform laparoscopic intraperitoneal morcellation should be aware of the recent US Food and Drug Administration (FDA) warning and litigation arising from use of morcellation devices with claims of intraperitoneal dissemination of cancerous cells. On November 24, 2014, the FDA issued a statement warning against using laparoscopic power morcellators in the majority of women undergoing hysterectomy or myomectomy for uterine fibroids. Despite the best intentions in regards to their patients, gynecologists who continue to use power morcellation devices expose themselves to liability. This article is not meant to further deter gynecologists from using laparoscopic power morcellators, but rather to provide an interpretation of the FDA statement as to the patients for whom the use of power morcellation may still be permitted under the FDA guidelines. This article also offers protective measures from a legal perspective for those who choose to continue to use power morcellation in the face of the recent FDA warning and litigation.",
keywords = "Boxed warning, Consent, FDA, Fibroids, Leiomyosarcoma, Liability, Litigation, Morcellation, Morcellator",
author = "Raquel Ton and Gokhan Kilic and John Phelps",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.jmig.2015.01.017",
language = "English (US)",
volume = "22",
pages = "564--572",
journal = "Journal of Minimally Invasive Gynecology",
issn = "1553-4650",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - A medical-legal review of power morcellation in the face of the recent FDA warning and litigation

AU - Ton, Raquel

AU - Kilic, Gokhan

AU - Phelps, John

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Minimally invasive gynecologic surgeons who perform laparoscopic intraperitoneal morcellation should be aware of the recent US Food and Drug Administration (FDA) warning and litigation arising from use of morcellation devices with claims of intraperitoneal dissemination of cancerous cells. On November 24, 2014, the FDA issued a statement warning against using laparoscopic power morcellators in the majority of women undergoing hysterectomy or myomectomy for uterine fibroids. Despite the best intentions in regards to their patients, gynecologists who continue to use power morcellation devices expose themselves to liability. This article is not meant to further deter gynecologists from using laparoscopic power morcellators, but rather to provide an interpretation of the FDA statement as to the patients for whom the use of power morcellation may still be permitted under the FDA guidelines. This article also offers protective measures from a legal perspective for those who choose to continue to use power morcellation in the face of the recent FDA warning and litigation.

AB - Minimally invasive gynecologic surgeons who perform laparoscopic intraperitoneal morcellation should be aware of the recent US Food and Drug Administration (FDA) warning and litigation arising from use of morcellation devices with claims of intraperitoneal dissemination of cancerous cells. On November 24, 2014, the FDA issued a statement warning against using laparoscopic power morcellators in the majority of women undergoing hysterectomy or myomectomy for uterine fibroids. Despite the best intentions in regards to their patients, gynecologists who continue to use power morcellation devices expose themselves to liability. This article is not meant to further deter gynecologists from using laparoscopic power morcellators, but rather to provide an interpretation of the FDA statement as to the patients for whom the use of power morcellation may still be permitted under the FDA guidelines. This article also offers protective measures from a legal perspective for those who choose to continue to use power morcellation in the face of the recent FDA warning and litigation.

KW - Boxed warning

KW - Consent

KW - FDA

KW - Fibroids

KW - Leiomyosarcoma

KW - Liability

KW - Litigation

KW - Morcellation

KW - Morcellator

UR - http://www.scopus.com/inward/record.url?scp=84926634656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926634656&partnerID=8YFLogxK

U2 - 10.1016/j.jmig.2015.01.017

DO - 10.1016/j.jmig.2015.01.017

M3 - Article

VL - 22

SP - 564

EP - 572

JO - Journal of Minimally Invasive Gynecology

JF - Journal of Minimally Invasive Gynecology

SN - 1553-4650

IS - 4

ER -